1. Home
  2. WNS vs SLNO Comparison

WNS vs SLNO Comparison

Compare WNS & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WNS
  • SLNO
  • Stock Information
  • Founded
  • WNS 1996
  • SLNO 1999
  • Country
  • WNS India
  • SLNO United States
  • Employees
  • WNS N/A
  • SLNO N/A
  • Industry
  • WNS Business Services
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • WNS Consumer Discretionary
  • SLNO Health Care
  • Exchange
  • WNS Nasdaq
  • SLNO Nasdaq
  • Market Cap
  • WNS 2.1B
  • SLNO 1.9B
  • IPO Year
  • WNS N/A
  • SLNO 2014
  • Fundamental
  • Price
  • WNS $50.75
  • SLNO $54.40
  • Analyst Decision
  • WNS Buy
  • SLNO Strong Buy
  • Analyst Count
  • WNS 7
  • SLNO 7
  • Target Price
  • WNS $60.43
  • SLNO $69.86
  • AVG Volume (30 Days)
  • WNS 574.1K
  • SLNO 529.2K
  • Earning Date
  • WNS 10-17-2024
  • SLNO 11-06-2024
  • Dividend Yield
  • WNS N/A
  • SLNO N/A
  • EPS Growth
  • WNS N/A
  • SLNO N/A
  • EPS
  • WNS 2.50
  • SLNO N/A
  • Revenue
  • WNS $1,308,696,000.00
  • SLNO N/A
  • Revenue This Year
  • WNS N/A
  • SLNO N/A
  • Revenue Next Year
  • WNS $7.96
  • SLNO N/A
  • P/E Ratio
  • WNS $21.84
  • SLNO N/A
  • Revenue Growth
  • WNS 2.07
  • SLNO N/A
  • 52 Week Low
  • WNS $39.85
  • SLNO $22.20
  • 52 Week High
  • WNS $72.57
  • SLNO $59.75
  • Technical
  • Relative Strength Index (RSI)
  • WNS 49.84
  • SLNO 50.19
  • Support Level
  • WNS $46.50
  • SLNO $55.62
  • Resistance Level
  • WNS $55.86
  • SLNO $59.75
  • Average True Range (ATR)
  • WNS 1.78
  • SLNO 2.06
  • MACD
  • WNS 0.68
  • SLNO -0.21
  • Stochastic Oscillator
  • WNS 45.41
  • SLNO 14.50

About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)

WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Share on Social Networks: